Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumeq in ALS (Lighthouse)
NCT02868580Phase 2Completed
- Sponsor
- Neuroscience Trials Australia
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abacavir in amyotrophic lateral sclerosis (ALS), sponsored by Neuroscience Trials Australia. Started Oct 2016; status: completed.
02
Drugs
abacavir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02868580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868580.